These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1409866)

  • 41. Simultaneous determination of plasma haloperidol and its metabolite reduced haloperidol by liquid chromatography with electrochemical detection. Plasma levels in schizophrenic patients treated with oral or intramuscular depot haloperidol.
    Aravagiri M; Marder SR; Van Putten T; Marshall BD
    J Chromatogr B Biomed Appl; 1994 Jun; 656(2):373-81. PubMed ID: 7987490
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum level monitoring and therapeutic effect of haloperidol in schizophrenic patients.
    Moulin MA; Davy JP; Debruyne D; Andersson JC; Bigot MC; Camsonne R; Poilpré E
    Psychopharmacology (Berl); 1982; 76(4):346-50. PubMed ID: 6812109
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hydroxyhaloperidol and clinical outcome in schizophrenia.
    Altamura AC; Mauri M; Cavallaro R; Regazzetti MG; Bareggi SR
    Psychopharmacol Ser; 1989; 7():263-8. PubMed ID: 2594731
    [No Abstract]   [Full Text] [Related]  

  • 44. Plasma haloperidol levels: clinical response and fancy mathematics.
    Van Putten T; Marder SR; Mintz J
    Arch Gen Psychiatry; 1985 Aug; 42(8):835-8. PubMed ID: 4015328
    [No Abstract]   [Full Text] [Related]  

  • 45. Steady-state pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients: analysis of factors determining their concentrations in hair.
    Uematsu T; Matsuno H; Sato H; Hirayama H; Hasegawa K; Nakashima M
    J Pharm Sci; 1992 Oct; 81(10):1008-11. PubMed ID: 1432610
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The interpretation of plasma haloperidol concentrations.
    Kirch DG; Bigelow LB; Wyatt RJ
    Arch Gen Psychiatry; 1985 Aug; 42(8):838-40. PubMed ID: 4015329
    [No Abstract]   [Full Text] [Related]  

  • 47. Reduced haloperidol/haloperidol ratio and clinical outcome in schizophrenia: preliminary evidences.
    Altamura C; Mauri M; Cavallaro R; Colacurcio F; Gorni A; Bareggi S
    Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(5):689-94. PubMed ID: 3222450
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical efficacy, extrapyramidal symptoms and serum levels: influence of administration schedules and concomitant drugs on serum bromperidol concentrations.
    Fujii Y; Tateyama M; Kamisada M; Tanoue A; Takamiya M; Nakajima S; Itoh H
    Folia Psychiatr Neurol Jpn; 1984; 38(2):121-36. PubMed ID: 6152433
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Haloperidol plasma levels and clinical response in paranoid schizophrenics.
    Linkowski P; Hubain P; von Frenckell R; Mendlewicz J
    Eur Arch Psychiatry Neurol Sci; 1984; 234(4):231-6. PubMed ID: 6526061
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of haloperidol and reduced haloperidol plasma levels in four different ethnic populations.
    Jann MW; Chang WH; Lam YW; Hwu HG; Lin HN; Chen H; Chen TY; Lin SK; Chien CP; Davis CM
    Prog Neuropsychopharmacol Biol Psychiatry; 1992 Mar; 16(2):193-202. PubMed ID: 1579637
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma noradrenaline and clinical psychopathology in schizophrenia. A correlation analysis.
    Dajas F; Barbeito L; Martinez-Pesquera G; Lista A; Puppo D; Puppo-Touriz H
    Neuropsychobiology; 1983; 10(2-3):70-4. PubMed ID: 6674828
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Analysis of the metabolism of haloperidol and its neurotoxic pyridinium metabolite in patients with drug-induced parkinsonism.
    Iwahashi K; Anemo K; Nakamura K; Fukunishi I; Igarashi K
    Neuropsychobiology; 2001; 44(3):126-8. PubMed ID: 11586051
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interindividual variabilities in haloperidol interconversion and the reduced haloperidol/haloperidol ratio.
    Lam YW; Chang WH; Jann MW; Chen H
    Neuropsychopharmacology; 1992 Aug; 7(1):33-9. PubMed ID: 1524655
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serum level of haloperidol and its clinical significance.
    Itoh H; Yagi G; Ohtsuka N; Iwamura K; Ichikawa K
    Prog Neuropsychopharmacol; 1980; 4(2):171-83. PubMed ID: 7403350
    [No Abstract]   [Full Text] [Related]  

  • 55. Total and free serum haloperidol levels in schizophrenic patients and the effect of age thioridazine and fatty acid on haloperidol-serum protein binding in vitro.
    Rowell FJ; Hui SM; Fairbairn AF; Eccleston D
    Br J Clin Pharmacol; 1981 Apr; 11(4):377-82. PubMed ID: 7259931
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High-performance liquid chromatography of haloperidol in serum at the concentrations achieved during chronic therapy.
    McBurney A; George S
    J Chromatogr; 1984 Jun; 308():387-92. PubMed ID: 6746832
    [No Abstract]   [Full Text] [Related]  

  • 57. Blood levels of reduced haloperidol versus clinical efficacy and extrapyramidal side effects of haloperidol.
    Lane HY; Lin HN; Hu OY; Chen CC; Jann MW; Chang WH
    Prog Neuropsychopharmacol Biol Psychiatry; 1997 Feb; 21(2):299-311. PubMed ID: 9061775
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The plasma levels of haloperidol and reduced haloperidol in Japanese psychiatric patients].
    Someya T; Shibasaki M; Takahashi S
    Yakubutsu Seishin Kodo; 1989 Jun; 9(2):207-15. PubMed ID: 2816093
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Radioimmunoassay of haloperidol in human serum: correlation of serum haloperidol with serum prolactin.
    Poland RE; Rubin RT
    Life Sci; 1981 Nov; 29(18):1837-45. PubMed ID: 7311717
    [No Abstract]   [Full Text] [Related]  

  • 60. Measurement of haloperidol and reduced haloperidol in human plasma using reversed-phase high-performance liquid chromatography.
    Miller RL; DeVane CL
    J Chromatogr; 1986 Jan; 374(2):405-8. PubMed ID: 3958099
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.